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Objective. Animal data suggest that cocaine has an immunosuppressive eﬀect, but no human studies have been conducted to
assess the relation of cocaine use with human papillomavirus (HPV) infection, the viral cause of cervical cancer. Since both
cocaine use and HPV infection are common among HIV-positive women, we sought to determine whether use of cocaine
and/or crack inﬂuences the natural history of HPV among women with or at high risk of HIV. Methods. Women enrolled
in the Women’s Interagency HIV Study (2278HIV-seropositive and 826 high-risk seronegative women) were examined every
six months for up to 9.5 years with Pap smear, collection of cervicovaginal lavage (CVL) samples, and detailed questionnaires
regarding health and behavior, including use of crack and cocaine (crack/cocaine). CVLs were tested for HPV DNA by PCR, with
genotyping for over forty HPV types. Results. In multivariate logistic regression models, censoring women treated for cervical
neoplasia, crack/cocaine use within the last six months was associated with prevalent detection of oncogenic HPV DNA (odds
ratio [OR] = 1.30 (1.09–1.55)), and with oncogenic HPV-positive squamous intraepithelial lesions (SIL) (OR = 1.70 (1.27–
2.27)), following adjustment for age, race, HIV-serostatus, and CD4+ T-cell count, the number of sexual partners in the past
six months, and smoking. In multivariate Cox models crack/cocaine use was also associated with a trend that approached
signiﬁcance in regard to incident detection of oncogenic HPV-positive SIL (HR = 1.51, 95% CI 0.99–2.30), and while the rate
of oncogenic HPV clearance was not related to cocaine use, the clearance of any SIL was signiﬁcantly lower in those with versus
those without recent crack/cocaine use (HR = 0.57, 95% CI 0.34–0.97). Conclusions. Cocaine use is associated with an increased
risk of detection of both prevalent and incident oncogenic HPV infection, as well as an increased risk of HPV-positive SIL over
time.
Copyright © 2008 Howard Minkoﬀ et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.2 Infectious Diseases in Obstetrics and Gynecology
1. INTRODUCTION
Human papillomavirus (HPV) infections of women, though
common, typically resolve. Persistence of oncogenic HPV
is necessary for the development of cervical precancer and
invasive cervical cancer (ICC). The incident detection and
persistence of HPV infections and related lesions have been
shown by us [1–4], and others [5–8], to be elevated among
HIV-seropositive compared to HIV-seronegative women,
and to be strongly associated with biomarkers of immune
statussuchasCD4+T-cellcountandHIVRNAlevelinHIV-
infected women.
Cocaine use is also common among HIV-infected
women [9, 10] and has been linked to perturbations of
the immune system in both animal models and humans
[11–13]. In one study of lymphocytes from individuals
with cocaine in their urine, it was found that “Memory”
CD8+ T cell subpopulations (i.e., CD45RO+) were reduced
in the cocaine-positive patients leading the authors to
concludethatthismight“representadisruptionofparticular
immunologic cell networks which could ultimately inﬂuence
host resistance to infection” [14]. Other researchers have
suggested that cocaine could inhibit the eﬀector functions
of neutrophils and macrophages, thus interfering with
the host’s ability to defend against infections, as well as
suppressing cytokine production, thereby diminishing the
capabilities of additional immune cells important in control
of viral infection [15–17].
Any disruption to host defenses attributable to cocaine,
in conjunction with those associated with HIV-infection per
se,couldincreasetheincidenceand/ordurationofoncogenic
HPVinfection.Thatinturncouldcontributetoanenhanced
risk of cervical neoplasia to which HIV-infected women are
demonstrably prone [18]. Additionally, if cocaine use was
found to modify the course of an infectious disease (such
as HPV), it would provide clinical evidence in support of
the assertion of researchers who, on the basis of results in
animal models, have expressed concerns about a potentially
enhanced susceptibility to infections among cocaine users in
general. In this paper, we take advantage of a large, well-
characterized cohort of HIV-infected and at risk women to
assess the association of cocaine use with HPV infection and
disease.
2. MATERIALS AND METHODS
The Women’s Interagency HIV Study (WIHS) is a prospec-
tive study of the natural history of HIV infection in
women that initially enrolled HIV-seropositive and at risk
seronegative women participants at six clinical sites (Bronx,
NY; Brooklyn, NY; Chicago; Los Angeles; San Francisco;
Washington, D.C.) between October 1994 and November
1995. A subsequent recruiting cycle occurred in 2002.
The recruitment methods and data collection procedures
f o rW I H Sh a v ep r e v i o u s l yb e e nd e s c r i b e d[ 19]. In brief,
participants underwent visits every six months that included
an interviewer-administered questionnaire, a physical exam-
ination, and the collection of specimens, including cervicov-
aginal lavage for HPV DNA testing. At each visit participants
were asked about drug use (types and frequency of use). At
baseline, they were asked about lifetime use as well as use in
the last six months. Questions were asked speciﬁcally about
cocaine and crack, as well as heroin and alcohol use. Those
who acknowledged the use of the drug were asked about the
average frequency of use (e.g., once a month, once a week,
once a day, etc.) over the last sixmonths.
There were a total of 3768 subjects in WIHS. We
excluded 16 subjects who had HIV seroconverted during
follow-up, and 253 subjects who did not have a cervix
present at baseline. Thus 3499 women were included. We
censoredallthevisitsafterhysterectomy.Thecurrentanalysis
includes women recruited in 1994/1995 and additional
women recruited in 2002. The initial recruits were tested
for HPV infection during visit 1 through visit 15, and the
more recent recruits were tested for HPV infection during
their baseline visit (V15 or V16) through visit 19. Eighty-
nine (9.7%) of the 915 HIV-seronegative women and 306
(11.8%) of the 2584 seropositive women did not have HPV
DNA test results available and were excluded from analysis.
Comparisons were made between HPV carriage patterns
(deﬁned below) of women who did or did not acknowledge
cocaine use.
2.1. Laboratorymethods
The laboratory technique for HPV assessments have been
described in detail elsewhere [20]. HPV DNA was detected
utilizing L1 consensus primer MY09/MY11/HMB01 poly-
merase chain reaction (PCR) assays [20–22]. Control primer
set PC04/GH20, amplifying a 268bp cellular beta globin
DNA fragment, was included in each assay to serve as
an internal control for ampliﬁcation. Following proteinase
K digestion, 2–10μL of each cell digest was used in
reactions containing 10mM Tris-HCL, 50mM KCL, 4mM
MgCl2, 200μM of each deoxyribonucleotide triphosphate,
2.5U Taq DNA polymerase, 0.5μMo fe a c hp r i m e r .T h e r e
were 40 ampliﬁcation cycles (95◦C for 20seconds, 55◦C
for 30seconds, and 72◦C for 30seconds, with a 5-minute
extension period at 72◦C on the last cycle). Ampliﬁed mate-
rial was then detected using ﬁlters individually hybridized
with biotinylated type-speciﬁc oligonucleotide probes for
multiple HPV types including HPV 6, 11, 16, 18, 26, 31,
32, 33, 35, 39, 40, 45, 51, 52, 53, 54 (AE9), 55, 56, 58,
59, 61, 62, 66, 67, 68, 69, 70, 71 (AE8), 72, 73 (PAP238A),
81 (AE7), 83(PAP291), 82v(AE2), 84 (PAP155), 85 (AE5),
and 89 (AE6), as described in [20, 23]. For these analyses,
oncogenic and nononcogenic HPV types were deﬁned in
accordance with recently published data that classiﬁed types
utilizing both phylogenetic and epidemiologic criterion. The
oncogenic HPVs were HPV-16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, and 66, and all other HPV types were considered
nononcogenic HPV [24].
PapsmearswerecollectedusingaplasticAyrespatulaand
an endocervical brush. Both specimens were smeared onto a
single slide and ﬁxed immediately. Cervical cytology samples
from all sites were centrally interpreted at Kyto Meridien
Laboratories (New York , NY) using the 1991 Bethesda
System criteria for cytologic diagnosis [25]. All smears wereHoward Minkoﬀ et al. 3
read by two cytotechnologists who were blinded to the
participants’ status. Ten percent of all negative smears and
a l la b n o r m a ls m e a r sw e r ec o n ﬁ r m e db yac y t o p a t h o l o g i s t .
Diagnoses were reported as normal or benign, atypical
squamous cells of uncertain signiﬁcance (ASCUS), low-
grade squamous intraepithelial lesion (LGSIL), moderate-
or high-grade squamous intraepithelial lesion (HGSIL),
and cancer. Glandular abnormalities were not included.
Whenever possible the primary cytologic outcome used was
SIL among women with oncogenic HPV. This was chosen
since SIL in the presence of HPV is more clearly a precursor
of cancer than are cases of SIL in which oncogenic HPV
is not detected. In cases in which the number of such
outcomes was sparse, we did use SIL among all women as an
outcome.
T-cell subsets were determined by immunoﬂuorescence
using ﬂow cytometry in laboratories participating in the
AIDS Clinical Trials Quality Assurance Program. Plasma
HIV RNA levels were measured using a nucleic acid
sequence-basedampliﬁcation(NASBA)technique(Organon
Teknika, Durham, NC, USA) with a lower threshold of
detection of 4000 copies/ml [26].
2.2. Statisticalanalysis
Cocaine used in the last six months was examined both as a
binary outcome (use/no use), and as an ordinal variable (no
use/less than once a month/once a month—once a week/2–
6 times a week/once a day or more). Consistent with prior
studies [4] the prevalence of HPV DNA was deﬁned as the
fraction of women with detectable HPV among those with
adequate HPV test results (as determined by the successful
ampliﬁcation of the human β-globin gene—see Laboratory
Methods). We deﬁned “incident detection” of HPV as
detection of an HPV type that was not found at baseline or at
any other earlier visit in a given woman. The term “incident
detection” is used instead of “incidence” to reﬂect the fact
that it is impossible to distinguish newly acquired HPV
infection and reactivation of previously acquired latent HPV
infection in a population with many years of sexual activity,
regardless of the HIV status of that population. Persistence
of HPV infection was deﬁned as the time to clearance
of a speciﬁc HPV type, and we further distinguished
in our analysis between the persistence of HPV detected
prevalently at baseline and those ﬁrst detected incidentally
at a subsequent visit (see below). Clearance itself was deﬁned
as either a single negative or two negative type-speciﬁc HPV
results at sequential visits. The ﬁndings were similar using
eitherapproachfordeﬁningclearance,andhereinwepresent
the results of clearance using the former deﬁnition.
The baseline characteristics of cocaine users and
nonusers in this study were examined, and the distributions
for selected parameters compared using standard Pearson
chi-square tests for categorical data, or by the Cochran-
Mantel-Haenszel tests when examining trends in ordinal
data. These variables were also evaluated as potential con-
founders in the multivariable analyses described below.
The association of cocaine use with prevalent HPV DNA
detection was measured in multivariate logistic regression
models that incorporated generalized estimating equations
(GEE) to adjust the standard errors for repeated measures
(i.e.,summarizingdataacrossallHPVtypesandacrossstudy
visits), and assuming an independent correlation structure.
In previous papers, we have shown that the results in this
dataset are unaltered by using other possible correlation
structures[4,27],and,ingeneral,modelestimatesarerobust
with respect to the correlation structure imposed [28].
Treatment of abnormal cervical cytology can introduce
a bias into analysis of HPV infection, since treatment can
alter the underlying mucosa; either increasing infection
(e.g., by exposing basal cells which are the cells susceptible
to infection) or decreasing infection (e.g., by removing
infected cells or inducing the replacement of columnar
with squamous tissue in the transformation zone of the
cervix). Censoring women at the time of cervical treatment
is commonly employed to address this bias and was used
in the analyses reported herein. Adjusting for therapy is an
alternate approach that was also used, but as the results were
in the same direction and of similar magnitude to those
found with censoring they are not presented. Other time-
dependent covariates included in our multivariate models
were CD4+ T-cell count, recent sexual behavior, smoking
status, and age group. Ethnicity was adjusted as a time-
independent variable.
Cox proportional-hazard regression models [29]w e r e
used to assess the association of cocaine use and the incident
detection of HPV. The event time was deﬁned as the mid-
point calendar date between the last HPV-negative and the
ﬁrst HPV-positive visit. Since each woman had been tested
for multiple HPV types at each visit time, Wei Lin Weissfeld
method was applied to adjust for possible correlations
between multiple incident infections [30]. A similar method
was used to measure the association of cocaine use with
time to clearance of HPV, stratiﬁed by whether the HPV
type was prevalent at baseline or was ﬁrst detected during
follow-up (incident detection). Time-dependent and time-
independentcovariates,aswellasmethodsforcontrollingfor
treatment of cervical neoplasia, were as described above.
Prevalent SIL and its association with cocaine use was
assessed using similar multivariate logistic regression models
incorporating GEE, as described above, to control repeated
observations over time. The associations of cocaine use and
incident detection of SILs were assessed using multivariate
Cox models.
3. RESULTS
This analysis included data from 2584 HIV-seropositive and
915 HIV-seronegative women. The median follow-up time
among those recruited during 1994-1995 was 10years and
for those recruited during 2002 was 3years; a total of 20849
person years of observation among HIV-seropositive and
6385 among HIV-seronegative women were included in this
analysis. At baseline 16.1% of participants reported use of
crack within the prior 6months, 11.5% had used cocaine,
and 6.9% had used both. The prevalence of HPV in the
cohort was 34.4%. Although we initially analyzed the eﬀects
of cocaine use on HPV infection separately from the eﬀects4 Infectious Diseases in Obstetrics and Gynecology
Table 1: Selected baseline characteristics of cocaine users and noncocaine users in last 6months at baseline in the Women’s Interagency HIV
Study∗.
Characteristic
N( % )
P-value Used crack/cocaine1 in last 6months
Yes No
Total 726 (%) 2761 (%) —
Age (yr) <.0001∗∗
<30 116 (16) 914 (33) —
30–34 160 (22) 680 (25) —
35–39 207 (29) 607 (22) —
40–44 171 (24) 339 (12) —
>=45 72 (10) 221 (8) —
Race <.0001
White 95 (13) 433 (16) —
Hispanic 121 (17) 829 (30) —
African American 494 (68) 1397 (51) —
Others 16 (2) 102 (4) —
HIV status and CD4 T-cell count 0.0559∗∗
HIV-negative 218 (31) 694 (26)
HIV-positive
CD4>500 150 (21) 664 (25) —
200≤CD4≤500 212 (30) 859 (32) —
CD4<200 121 (17) 490 (18) —
Number of male sex partners in past 6 months <.0001∗∗
0 155 (22) 772 (28) —
1 (married) 80 (11) 506 (18) —
1 (single) 223 (31) 1049 (38) —
2 97 (14) 266 (10) —
>2 160 (22) 159 (6) —
Smoking status <.0001∗∗
None 60 (8) 1106 (40) —
Former smoker 37 (5) 483 (18) —
Current smoker <10 pack-years 282 (39) 706 (26) —
Current smoker >=10 pack-years 344 (48) 456 (17) —
Frequency of crack/cocaine use
Less than once per month 131 (18) NA —
Once per month—once per week 224 (31) NA —
2–6 times per week 185 (25) NA —
Once per day or more 180 (25) NA —
∗Limited to those contributing data to the present analysis. Some data were missing at baseline for selected patients. Percentages do not always add up to
100% due to rounding.
∗∗Two-sided Cochran-Mantel-Haenszel test. All other P values were determined with the two-sided Pearson’s chi-square test.
of crackuse,no signiﬁcant (or otherwise notable) diﬀerences
were observed (data not shown). Therefore, we combined
these data, and herein report a comparison of the prevalence,
incidence and time to clearance of HPV among women
who used either cocaine or crack (crack/cocaine use) to that
among women who used neither drug.
Table 1 shows the demographic characteristics of the
study population at baseline. Women acknowledging
crack/cocaine use were older, more likely to be African
Americans, less likely to be Hispanic, had more sex partners
in the last six months, and were more likely to report heavy
cigarette use. Among women who reported crack/cocaine
during the past 6 months, 18% reported using less than
once per month (<once/mo), 31% reported using between
once/month and once/week (once/mo-once/wk), 25% 2–6
times per week (2–6/wk), and 25% once per day or more
(≥once/day).
Prevalent detection of oncogenic HPV was signiﬁcantly
more common among women who reported crack/cocaine
use during the prior 6months (Table 2), than women who
did not use either drug (OR = 1.30; [95% CI: 1.09–1.55]),
after adjustment for age, race, HIV serostatus and CD4+Howard Minkoﬀ et al. 5
Table 2: Association of crack and cocaine use with prevalence, incidence, and clearance of human papillomavirus (HPV) and cervical
squamous intraepethelial lesions (SIL) (adjusted analysis∗).
Crack or cocaine use in the past six months Any HPV Oncogenic HPV Nononcogenic HPV SIL with oncogenic HPV
Prevalent HPV and SIL: OR (95% CI)
No 1.0 1.0 1.0 1.0
Yes 1.22 (1.09–1.37) 1.30 (1.09–1.55) 1.18 (1.04–1.34) 1.70 (1.27–2.27)
Incident HPV and SIL: HR (95% CI)
No 1.0 1.0 1.0 1.0
Yes 1.20 (1.02–1.42) 1.21 (0.97–1.52) 1.20 (1.00–1.44) 1.51 (0.99–2.30)
Clearance of HPV and SIL∗∗: HR (95% CI)
No 1.0 1.0 1.0 1.0
Yes 1.02 (0.88–1.17) 0.96 (0.80–1.16) 1.05 (0.88–1.25) 0.57 (0.34–0.97)
∗Adjusted for CD4 count, number of sexual partners, smoking, age and race.
∗∗As there were a limited number of SIL infections with oncogenic HPV for analysis of SIL clearance, results presented for risk of SIL clearance include all
SIL observed with or without oncogenic HPV.
T-cell count, the number of sexual partners during the
prior 6 months, and smoking behavior, all factors that
we found to be associated with cervical HPV detection in
prior studies [4, 31]. Nononcogenic HPV was also more
prevalent among crack/cocaine users; OR= 1.18 (1.04–1.34).
Oncogenic HPV-positive cervical neoplasia (i.e., squamous
intraepithelial lesions [SIL] at risk of progression [oncogenic
HPV+ SIL]) was also signiﬁcantly more common among
women who reported crack/cocaine use during the prior
6months (Table 2;O R= 1.63; 95% CI 1.20–2.21).
Incident detection of oncogenic HPV was increased
among crack/cocaine users, although the relationship did
not reach signiﬁcance at traditional values (Table 2; hazard
ratio [HR] = 1.21, 0.97–1.52). Similar results were observed
for incident detection of nononcogenic HPV and any
HPV (Table 2). Crack/cocaine was also associated with a
trend that approached signiﬁcance in regard to an elevated
risk of incident oncogenic HPV+ SIL (OR 1.51; 95%
CI: 0.99–2.30).
ClearanceofoncogenicHPVinfectionwasnotassociated
with crack/cocaine use during the prior 6months (Table 2).
Similarly, no association was found between cocaine use
and clearance of HPV+ SIL, although the data were sparse
given the more limited occurrence of this endpoint (data not
shown). Therefore, we assessed associations between cocaine
useandanySIL(withorwithoutoncogenicHPV).Wefound
asigniﬁcantassociationbetweendelayedclearanceofSILand
cocaine use, (HR 0.57; 95% CI 0.34–0.97). No statistically
signiﬁcant dose response was seen with any of the outcomes
when frequency of cocaine use was assessed as an ordinal
variable (data not shown).
Similar analyses were performed for alcohol and heroin
use.Noassociationwasfoundbetweeneitherdrugs(whether
we considered exposure as a dichotomous or as an ordinal
variable) and any of the outcomes of interest (oncogenic or
nononcogenic HPV, or SIL).
4. DISCUSSION
In this prospective study of HIV-infected and HIV-uni-
nfected women, we observed increased risk of oncogenic and
nononcogenic HPV infection in those with crack/cocaine
use but not in those with heroin or alcohol use, consistent
with our a priori hypothesis. If correct, the data suggest
that the immunologic eﬀects of cocaine, previously reported
primarily in animal models, may have relevance to humans.
Shen and colleagues, evaluating a mouse model in
which cocaine was injected intraperitoneally found that all
immune parameters, other than lymphocyte transformation
of the splenic or the peripheral blood lymphocytes, were
suppressed [11]. Other investigators have shown that with-
drawal from cocaine can also induce deleterious immune
alterations. Using a rat model, Avila demonstrated that
repeated exposure to cocaine followed by withdrawal led
to activation of the neuroendocrine stress response, which
alters cellular immunity and possibly contributes to an
increased susceptibility to infection [13] .H P Vi nh u m a n si s
felt to be controlled, at least in part, by an intact mucosal
immune system [32]. Perhaps most germane to our ﬁndings
is the work of Lopez [33] and colleagues, who found that
daily cocaine administration induced a signiﬁcant decrease
in the number of IgA+ cells with a concomitant increase
in the number of CD8+ cells per villi in the intestinal
lamina propria (ILP). Murine retrovirus infection alone
decreased the number of IgA+ and CD4+ cells in the ILP,
and this decrease was even more marked when murine
acquired immune deﬁciency syndrome (MAIDS) mice also
received cocaine. The authors concluded that, “cocaine
administration could potentiate the dramatic eﬀect that
MAIDS infection has on the mucosal-associated lymphoid
tissues” [33].
These data suggest that response to HPV infection
might be altered by cocaine. While HIV-infected women are
already at immunologic jeopardy and prone to numerous
coinfections, the relationship between cocaine use and HPV,
one of the most common sexually transmitted infections,
has not, to our knowledge, been the focus of prior research.
While we and others have considered drug use as a covariate
in studies of HPV infections, those studies have often not
looked speciﬁcally at cocaine or crack, controlled for other
factors, or used drug use as a primary focus of analysis
[20]. Our data appear to conﬁrm the immunomodulatory6 Infectious Diseases in Obstetrics and Gynecology
eﬀectsofcocaine,andsuggestthatfurtherclinical/laboratory
research is indicated to better understand the associations
between cocaine use and the detection, and natural history
of HPV infection as well as the mechanism that underpins
the relationship.
This study had several limitations. The ﬁnding of
increased detection of HPV among women acknowledging
cocaine or crack use could reﬂect either an immunologic
phenomenon or a behavioral one (i.e., increased sexual
activity) despite our eﬀorts to control this in our analyses.
However, we did not ﬁnd a similar relationship between
HPV and the use of other drugs that might also be markers
of risk taking. Our failure to detect a consistent biologic
gradient in cocaine’s eﬀect (there was an increasing eﬀect
with increasing exposure except at the highest strata when
sample size became small; data not shown) suggests that
cautionmustbeexercisedininterpretationofresultsandthat
further work is warranted to conﬁrm and potentially extend
these ﬁndings.
An additional limitation to this study is our inability
to provide biologic measures of drug exposure. We note,
however, that the same study personnel performed repeated
interviews over the course of the study and formed a
close rapport with the WIHS participants. Further, we have
previously observed a close correlation of acknowledged
drug use and reliable surrogates (e.g., use of injection
drugs and hepatitis C infection, data not shown). More
importantly, it is most likely that misclassiﬁcation would
have been in the direction of understating the frequency of
drug use, which would most likely have biased our results
toward the null. A ﬁnal concern is that, since we have
previously shown that HAART use can modify the course of
HPV disease [34], it is possible that some of the perceived
eﬀect of cocaine may have been mediated by a lower rate of
medication adherence among cocaine users. To investigate
this possibility, we repeated the analyses described above,
but limited only to the time frame prior to the availability
of HAART. All ﬁndings were in the same direction (data
not shown) as reported for the time frame after HAART
became available. Thus, compliance with HAART use would
not seem to be an explanation for our ﬁndings.
In summary, our data suggest an association of
crack/cocaine use with increased prevalence, incidence, and
delayed time to clearance of oncogenic HPV among HIV-
infected women and women at risk of HIV. These data lend
support to animal studies suggesting a link between cocaine
use and predilection to infections and add to the litany of
reasons for making drug treatment a component of the care
of HIV-infected individuals.
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